GlassScriptPhysician profile
Rutwik Patel
NPI 1619536455
$4,753.78
in general payments reported to CMS, 2019-2025
28 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.05 · 2020: $553 · 2021: $444 · 2022: $26.60 · 2023: $2,338 · 2024: $674 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198 · Travel and Lodging: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.84 |
| Travel and Lodging | $1,449.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,707.18 | 2023-2025 | Inspire |
| Olympus Corporation of The Americas | $1,008.61 | 2023 | Single Use Suction Valve (Sterile) |
| Glaxosmithkline, LLC. | $504.73 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $158.25 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $61.52 | 2023-2025 | |
| Grifols USA, LLC | $55.55 | 2023-2024 | Prolastin-C Liquid, Xembify |
| Harmony Biosciences LLC | $50.40 | 2023-2024 | Wakix |
| Insmed, INC. | $47.76 | 2024-2025 | Arikayce |
| Ani Pharmaceuticals, INC. | $47.42 | 2023-2024 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $45.10 | 2023-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.49 | 2025 | Ofev |
| Abiomed | $42.46 | 2024 | Impella |
| United Therapeutics Corporation | $38.67 | 2024 | Tyvaso |
| Mylan Specialty L.P. | $30.15 | 2023-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $28.48 | 2025 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $27.20 | 2023 | Wegovy |
| Avadel Cns Pharmaceuticals, LLC | $27.09 | 2025 | Lumryz |
| Genentech USA, INC. | $20.74 | 2024 | Xolair |
| Shionogi INC | $20.59 | 2024 | Fetroja |
| Baxter Healthcare | $18.59 | 2023 | Hillrom - Life 2000 Ventilation System |
| Resmed Corp | $18.47 | 2025 | |
| Philips North America LLC | $18.33 | 2023 | |
| Viatris Specialty LLC | $17.29 | 2025 | Yupelri |
| Lilly USA, LLC | $17.29 | 2025 | Zepbound |
| Siemens Medical Solutions USA, INC. | $16.66 | 2024 | Cios Spin |
| Verona Pharma, INC. | $16.47 | 2025 | Ohtuvayre |
| Amgen INC. | $14.91 | 2024 | Tezspire |
| Electromed, INC. | $14.07 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rutwik Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.